全文获取类型
收费全文 | 1038篇 |
免费 | 95篇 |
国内免费 | 6篇 |
专业分类
耳鼻咽喉 | 13篇 |
儿科学 | 32篇 |
妇产科学 | 16篇 |
基础医学 | 98篇 |
口腔科学 | 198篇 |
临床医学 | 104篇 |
内科学 | 183篇 |
皮肤病学 | 23篇 |
神经病学 | 34篇 |
特种医学 | 99篇 |
外科学 | 101篇 |
综合类 | 23篇 |
预防医学 | 114篇 |
眼科学 | 9篇 |
药学 | 24篇 |
中国医学 | 1篇 |
肿瘤学 | 67篇 |
出版年
2023年 | 11篇 |
2022年 | 8篇 |
2021年 | 21篇 |
2020年 | 18篇 |
2019年 | 18篇 |
2018年 | 27篇 |
2017年 | 34篇 |
2016年 | 28篇 |
2015年 | 41篇 |
2014年 | 51篇 |
2013年 | 63篇 |
2012年 | 43篇 |
2011年 | 60篇 |
2010年 | 55篇 |
2009年 | 31篇 |
2008年 | 49篇 |
2007年 | 53篇 |
2006年 | 38篇 |
2005年 | 29篇 |
2004年 | 33篇 |
2003年 | 23篇 |
2002年 | 23篇 |
2001年 | 27篇 |
2000年 | 17篇 |
1999年 | 22篇 |
1998年 | 29篇 |
1997年 | 35篇 |
1996年 | 30篇 |
1995年 | 18篇 |
1994年 | 19篇 |
1993年 | 13篇 |
1992年 | 11篇 |
1991年 | 7篇 |
1990年 | 9篇 |
1989年 | 11篇 |
1988年 | 8篇 |
1987年 | 8篇 |
1986年 | 9篇 |
1985年 | 12篇 |
1984年 | 9篇 |
1983年 | 6篇 |
1982年 | 14篇 |
1981年 | 8篇 |
1980年 | 11篇 |
1979年 | 6篇 |
1978年 | 7篇 |
1977年 | 8篇 |
1976年 | 7篇 |
1975年 | 6篇 |
1973年 | 4篇 |
排序方式: 共有1139条查询结果,搜索用时 171 毫秒
41.
42.
I Bendit SS Sanabani M Conchon M Serpa MM Novaes L Nardinelli TD Pereira L Tucunduva PD Ferreira PE Dorlhiac-Llacer DD Fischer Chamone 《Acta haematologica》2012,128(4):223-232
Here we compare the management and survival outcomes of chronic myeloid leukemia (CML) patients who had early or late imatinib mesylate (IM) therapy. The cytogenetic and molecular responses of 189 CML patients were analyzed. Of this group, 121 patients were classified as the early chronic phase (ECP) group and started IM within 12 months of diagnosis. The other 68 patients were classified as the late chronic phase (LCP) group who had been treated with interferon (IFN)-alpha-2 and crossed over to IM more than 12 months after diagnosis. The overall rates of complete cytogenetic response (CCyR) and major molecular response (MMR) at last follow-up were 83.6 and 78.1% in the ECP and LCP groups, respectively. The CCyR rates were 89.3 (for ECP patients) versus 73.5% (for LCP patients; p < 0.0001). At last follow-up, 82.4% ECP and 64.2% LCP patients had achieved an MMR (p < 0.0001). No significant differences were noted between the two groups with regard to survival outcomes. Our experience reveals that IM is an effective rescue therapy in most CML LCP patients who are intolerant or in whom IFN-alpha therapy fails. Such therapeutic options should be considered in LCP patients, particularly in countries where IM may not be available. 相似文献
43.
Willian Oliveira Fahl Pedro Carnieli Juliana Galera Castilho Maria Luiza Carrieri Ivanete Kotait Keila Iamamoto Rafael Novaes Oliveira Paulo Eduardo Brandão 《The Brazilian journal of infectious diseases》2012,16(6):545-551
In Brazil, bats have been assigned an increasing importance in public health as they are important rabies reservoirs. Phylogenetic studies have shown that rabies virus (RABV) strains from frugivorous bats Artibeus spp. are closely associated to those from the vampire bat Desmodus rotundus, but little is known about the molecular diversity of RABV in Artibeus spp. The N and G genes of RABV isolated from Artibeus spp. and cattle infected by D. rotundus were sequenced, and phylogenetic trees were constructed. The N gene nucleotides tree showed three clusters: one for D. rotundus and two for Artibeus spp. Regarding putative N amino acid-trees, two clusters were formed, one for D. rotundus and another for Artibeus spp. RABV G gene phylogeny supported the distinction between D. rotundus and Artibeus spp. strains. These results show the intricate host relationship of RABV's evolutionary history, and are invaluable for the determination of RABV infection sources. 相似文献
44.
45.
46.
47.
Femke?DH?Koedijk Birgit?HB?van BenthemEmail author Eliane?MDC?Vrolings Wim?Zuilhof Marianne?AB?van der Sande 《Emerging themes in epidemiology》2014,11(1):12
Background
Men having sex with men (MSM) remain the largest high-risk group involved in on-going transmission of sexually transmitted infections (STI), including HIV, in the Netherlands. As risk behaviour may change with age, it is important to explore potential heterogeneity in risks by age. To improve our understanding of this epidemic, we analysed the prevalence of and risk factors for selected STI in MSM attending STI clinics in the Netherlands by age group.Methods
Analysis of data from the national STI surveillance system for the period 2006–2012. Selected STI were chlamydia, gonorrhoea, infectious syphilis and/or a new HIV infection. Logistic regression was used to identify factors associated with these selected STI and with overall STI positivity. Analyses were done separately for MSM aged younger than 25 years and MSM aged 25 years and older.Results
In young MSM a significant increase in positivity rate was seen over time (p?<?0.01), mainly driven by increasing gonorrhoea diagnoses, while in MSM aged 25 and older a significant decrease was observed (p?<?0.01). In multivariate analyses for young MSM, those who were involved in commercial sex were at higher risk (OR: 1.5, 95% CI: 1.2-1.9). For MSM aged 25 years and older this was not the case. Having a previous negative HIV test was protective among older MSM compared to those not tested for HIV before (OR: 0.8, 95% CI: 0.8-0.8), but not among younger MSM.Conclusions
MSM visiting STI clinics remain a high-risk group for STI infections and transmission, but are not a homogenous group. While in MSM aged older than 25 years, STI positivity rate is decreasing, positivity rate in young MSM increased over time. Therefore specific attention needs to be paid towards targeted counselling and reaching particular MSM sub-groups, taken into account different behavioural profiles.48.
Autoantibody against erythrocyte protein 4.1 in a patient with autoimmune hemolytic anemia 总被引:1,自引:0,他引:1
Wakui H; Imai H; Kobayashi R; Itoh H; Notoya T; Yoshida K; Nakamoto Y; Miura AB 《Blood》1988,72(2):408-412
We observed the presence of a new autoantibody, anti-erythrocyte protein 4.1, in a patient with autoimmune hemolytic anemia (AIHA). Western blotting analysis revealed that IgG from the patient's plasma reacted with erythrocyte protein 4.1. However, among other patients with hemolytic diseases (six having AIHA and three each having either hereditary spherocytosis, elliptocytosis, or lead poisoning) as well as among control subjects, no antibody activity to protein 4.1 was observed. In addition to the anti-protein 4.1 antibody, two different kinds of anti-erythrocyte antibodies were detected by conventional serological studies in this patient. One of them was an anti-Ena-like antibody in the eluate from the patient's erythrocytes, while another was the anti-S-specific antibody in the plasma. An elution study and an absorption study using S antigen-positive erythrocytes demonstrated that the anti-protein 4.1 antibody differed from both the anti-Ena-like antibody and the anti-S antibody. Familial analysis of the patient revealed the same antibody in her brother, who did not have hemolytic anemia. These results demonstrate that anti-protein 4.1 antibody is considered to be included in the spectrum of anti-cytoskeleton autoantibodies, which have been observed in patients having increased cell lysis as well as in healthy subjects. 相似文献
49.
Deisseroth AB; Zu Z; Claxton D; Hanania EG; Fu S; Ellerson D; Goldberg L; Thomas M; Janicek K; Anderson WF 《Blood》1994,83(10):3068-3076
Relapse after autologous bone marrow transplantation for chronic myelogenous leukemia (CML) can be due either to the persistence of leukemia cells in systemic tissues following preparative therapy, or due to the persistence of leukemia cells in the autologous marrow used to restore marrow function after intensive therapy. To help distinguish between these two possible causes of relapse, we used safety-modified retroviruses, which contain the bacterial resistance gene NEO, to mark autologous marrow cells that had been collected from patients early in the phase of hematopoietic recovery after in vivo chemotherapy. The cells were then subjected to ex vivo CD34 selection following collection and 30% of the bone marrow were exposed to a safety-modified virus. This marrow was infused after delivery of systemic therapy, which consisted of total body irradiation (1,020 cGy), cyclophosphamide (120 mg/kg), and VP-16 (750 mg/m2). RT PCR assays specific for the bacterial NEO mRNA, which was coded for by the virus, and the bcr-abl mRNA showed that in two evaluable CML patients transplanted with marked cells, sufficient numbers of leukemia cells remained in the infused marrow to contribute to systemic relapse. In addition, both normal and leukemic cells positive for the retroviral transgenome persisted in the systemic circulation of the patients for at least 280 days posttransplant showing that the infused marrow was responsible for the return of hematopoiesis following the preparative therapy. This observation shows that it is possible to use a replication-incompetent safety-modified retrovirus in order to introduce DNA sequences into the hematopoietic cells of patients undergoing autologous bone marrow transplantation. Moreover, this data suggested that additional fractionation procedures will be necessary to reduce the probability of relapse after bone marrow transplantation in at least the advanced stages of the disease in CML patients undergoing autologous bone marrow transplantation procedures. 相似文献